Tenofovir Disoproxil Fumarate

富马酸替诺福韦二吡呋酯

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameTenofovir Disoproxil Fumarate
Drug Alias Name富马酸替诺福韦替诺福韦酯富马酸替诺福韦酯富马酸泰诺福韦酯Tenozet +[15] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitorsHBV DNA Polymerase inhibitors
TargetsReverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsMedication AdherenceNutrition DisordersMetabolic Diseases +[13] 
Global Approved IndicationsHepatitis BVirus DiseasesHIV Infections
Approved Indications in ChinaVirus Diseases
Original Approved Country/TerritoryUnited States
Original Approved Date2001/10/26
Country/TerritoryCzechiaBulgariaCanada +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesJapan Tobacco (Hong Kong) LtdEastern Virginia Medical SchoolGlaxosmithkline Plc +[13] 
Inactive CompaniesPublic Health Foundation Enterprises IncInje UniversityNational Cancer Institute +[8] 
Active IndicationsMedication AdherenceCarcinoma, HepatocellularHepatitis B, Chronic +[7] 
Inactive IndicationsNutrition DisordersMetabolic DiseasesLipodystrophy +[6] 

Other Information

ATC CodeJ05AF07
Related LinksN/A